NT 0007
Alternative Names: NT-0007Latest Information Update: 11 Mar 2024
At a glance
- Originator Nucleome Therapeutics
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Multiple sclerosis; Systemic lupus erythematosus
Most Recent Events
- 18 Jan 2024 NT 0007 is available for licensing as of 18 Jan 2024. https://nucleome.com/innovation/
- 18 Jan 2024 Early research in Multiple sclerosis in United Kingdom (unspecified route) (Nucleome Therapeutics pipeline, January 2024)
- 18 Jan 2024 Early research in Systemic lupus erythematosus in United Kingdom (unspecified route) (Nucleome Therapeutics pipeline, January 2024)